InnoCan PharmaINNPF -10.53%56 PB Ratio is 1.47 as of Jun. 29, 2026, which is 86% below its 10-year median of 10.86. GuruFocus rates INNPF with a GF Score™ of 56/100 and a GF Value™ of $10.03 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,895 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 58.1% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), InnoCan Pharma's share price is $1.70. InnoCan Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $1.16. Hence, InnoCan Pharma's PB Ratio of today is 1.47.
Good Sign:
InnoCan Pharma Corp stock PB Ratio (=1.62) is close to 10-year low of 1.62.
The historical rank and industry rank for InnoCan Pharma's PB Ratio or its related term are showing as below:
INNPF'
s PB Ratio Range Over the Past 10 Years
Min: 1.62 Med: 10.86 Max: 138.51
Current: 1.62
During the past 8 years, InnoCan Pharma's highest PB Ratio was 138.51. The lowest was 1.62. And the median was 10.86.
INNPF's PB Ratio is ranked worse than 58.1% of 1895
companies
in the Consumer Packaged Goods industry
Industry Median: 1.33
vs INNPF: 1.62
During the past 12 months, InnoCan Pharma's average Book Value Per Share Growth Rate was 5.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.80% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of InnoCan Pharma was 240.20% per year. The lowest was -18.40% per year. And the median was 15.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
InnoCan Pharma PB Ratio Related Terms
InnoCan Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, InnoCan Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma PB Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
InnoCan Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
InnoCan Pharma (INNPF) has a PB Ratio of 1.47 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on InnoCan Pharma and its competitors. This is 86% below median its historical median of 10.86. Over the past decade, InnoCan Pharma's PB Ratio has ranged from 1.62 to 138.51. According to the industry distribution chart, InnoCan Pharma ranks #1101 out of 1895 companies in the Consumer Packaged Goods industry, placing it in the top 58.1%.
Is InnoCan Pharma's PB Ratio too high?
InnoCan Pharma's current PB Ratio of 1.47 is 86% below median its 10-year median of 10.86. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 138.51. The Consumer Packaged Goods industry median PB Ratio is 1.33. InnoCan Pharma's value of 1.47 is 10.5% above this industry median. Based on the distribution chart, InnoCan Pharma ranks #1101 out of 1895 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's PB Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1101 out of 1895 companies for PB Ratio. This places InnoCan Pharma in the lower half of its industry. The industry median PB Ratio is 1.33. InnoCan Pharma's value of 1.47 is 10.5% above this benchmark. Historically, InnoCan Pharma's own PB Ratio has ranged from 1.62 to 138.51 over the past decade. While the company's 10-year median is 10.86 vs. the industry median of 1.33, InnoCan Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Consumer Packaged Goods company?
The median PB Ratio among Consumer Packaged Goods companies is 1.33, based on 1,895 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current PB Ratio of 1.47 is 10.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median PB Ratio is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current PB Ratio is 1.47, which is 86% below median its own 10-year median of 10.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (INNPF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.03, compared to a current price of $1.70 — trading 83.1% below its estimated fair value. The current PB Ratio is 1.47, which is 86% below median its 10-year median of 10.86 and 10.5% above the Consumer Packaged Goods industry median of 1.33. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For InnoCan Pharma (INNPF), the current PB Ratio is 1.47 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (INNPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of $1.70 is trading 83.1% below its estimated GF Value™ of $10.03.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for INNPF:
PB Ratio: 1.47 (86% below median its 10-year median of 10.86)
GF Value™: $10.03 vs. price of $1.70 (83.1% below fair value)
Industry Position: 10.5% above the Consumer Packaged Goods median (#1101 of 1895)
No single metric tells the full story. See the INNPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
56GF Score
Get the complete analysis for INNPF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INNPF has been successfully added to your 
